These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

721 related items for PubMed ID: 15742545

  • 21. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
    Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB.
    J Clin Oncol; 2010 Mar 10; 28(8):1294-300. PubMed ID: 20142601
    [Abstract] [Full Text] [Related]

  • 22. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial.
    Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA.
    Cancer; 2004 Jun 01; 100(11):2292-9. PubMed ID: 15160331
    [Abstract] [Full Text] [Related]

  • 23. Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
    Schilder CM, Schagen SB.
    Minerva Ginecol; 2007 Aug 01; 59(4):387-401. PubMed ID: 17923830
    [Abstract] [Full Text] [Related]

  • 24. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study.
    Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB.
    Psychooncology; 2012 May 01; 21(5):479-87. PubMed ID: 21351188
    [Abstract] [Full Text] [Related]

  • 25. Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?
    Buwalda B, Schagen SB.
    Life Sci; 2013 Oct 17; 93(17):581-8. PubMed ID: 23353876
    [Abstract] [Full Text] [Related]

  • 26. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer.
    Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E.
    Clin Neuropsychol; 2006 Feb 17; 20(1):76-89. PubMed ID: 16410227
    [Abstract] [Full Text] [Related]

  • 27. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE.
    Cancer; 2004 Sep 15; 101(6):1311-22. PubMed ID: 15368322
    [Abstract] [Full Text] [Related]

  • 28. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
    Rodríguez-Rodríguez LM, Rodríguez-Rodríguez EM, Oramas-Rodríguez JM, Santolaria-Fernandez F, Llanos M, Cruz J, Martínez A, González-Reimers E, Gómez A, Batista N.
    Breast Cancer Res Treat; 2005 Sep 15; 93(1):75-83. PubMed ID: 16184462
    [Abstract] [Full Text] [Related]

  • 29. One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer.
    Noal S, Levy C, Hardouin A, Rieux C, Heutte N, Ségura C, Collet F, Allouache D, Switsers O, Delcambre C, Delozier T, Henry-Amar M, Joly F.
    Int J Radiat Oncol Biol Phys; 2011 Nov 01; 81(3):795-803. PubMed ID: 20888704
    [Abstract] [Full Text] [Related]

  • 30. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB, Feuer EJ, Harlan LC, Abrams J.
    J Natl Cancer Inst Monogr; 2006 Nov 01; (36):7-15. PubMed ID: 17032888
    [Abstract] [Full Text] [Related]

  • 31. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment.
    Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S.
    Psychooncology; 2009 Feb 01; 18(2):134-43. PubMed ID: 18551510
    [Abstract] [Full Text] [Related]

  • 32. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R, European Organisation for Research and Treatment of Cancer Breast Group, Scottish Breast Cancer Trials Group.
    Eur J Cancer; 2007 Jan 01; 43(2):331-40. PubMed ID: 17134892
    [Abstract] [Full Text] [Related]

  • 33. Cognitive Deficits in Breast Cancer Survivors After Chemotherapy and Hormonal Therapy.
    Frank JS, Vance DE, Triebel KL, Meneses KM.
    J Neurosci Nurs; 2015 Dec 01; 47(6):302-12. PubMed ID: 26447567
    [Abstract] [Full Text] [Related]

  • 34. Predictors of cognitive decline after chemotherapy in breast cancer patients.
    Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G.
    J Int Neuropsychol Soc; 2009 Nov 01; 15(6):951-62. PubMed ID: 19709455
    [Abstract] [Full Text] [Related]

  • 35. The effects of adjuvant chemotherapy on cognition in women with breast cancer--preliminary results of an observational longitudinal study.
    Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D.
    Breast; 2005 Apr 01; 14(2):142-50. PubMed ID: 15767184
    [Abstract] [Full Text] [Related]

  • 36. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer.
    Kreukels BP, van Dam FS, Ridderinkhof KR, Boogerd W, Schagen SB.
    Clin Breast Cancer; 2008 Feb 01; 8(1):80-7. PubMed ID: 18501062
    [Abstract] [Full Text] [Related]

  • 37. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study.
    Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K.
    Cancer; 2008 Nov 01; 113(9):2431-9. PubMed ID: 18823033
    [Abstract] [Full Text] [Related]

  • 38. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: 'subjective' complaints and 'objective' neuropsychological test results.
    Weis J, Poppelreuter M, Bartsch HH.
    Psychooncology; 2009 Jul 01; 18(7):775-82. PubMed ID: 19061196
    [Abstract] [Full Text] [Related]

  • 39. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P.
    Clin Cancer Res; 1995 Feb 01; 1(2):189-98. PubMed ID: 9815973
    [Abstract] [Full Text] [Related]

  • 40. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L, Bendahl PO, Grabau D, Isola J, Lövgren K, Rydén L, Fernö M.
    Breast Cancer Res Treat; 2008 May 01; 109(2):255-62. PubMed ID: 17636398
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.